{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:11:46Z","timestamp":1770135106545,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Renal Nutrition"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1053\/j.jrn.2013.11.004","type":"journal-article","created":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T12:34:02Z","timestamp":1390566842000},"page":"105-109","source":"Crossref","is-referenced-by-count":18,"title":["Reasons for Phosphate Binder Discontinuation Vary by Binder Type"],"prefix":"10.1053","volume":"24","author":[{"given":"Steven","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel A.","family":"Anum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Braunhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britt","family":"Newsome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jrn.2013.11.004_bib1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2013.11.004_bib2","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2013.11.004_bib3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2013.11.004_bib4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1053\/j.ajkd.2005.05.025","article-title":"Relationship of phosphorus and calcium-phosphorus product with mortality in CKD","volume":"46","author":"Menon","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2013.11.004_bib5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1523-1755.2003.00064.x","article-title":"Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS","volume":"64","author":"Saran","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2013.11.004_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"4 suppl 3","key":"10.1053\/j.jrn.2013.11.004_bib7","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"5 suppl 2","key":"10.1053\/j.jrn.2013.11.004_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0272-6386(04)01103-5","article-title":"Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"44","author":"Young","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2013.11.004_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1755-6686.2012.00233.x","article-title":"Focused clinical campaign improves mineral and bone disorder outcomes","volume":"38","author":"Benner","year":"2012","journal-title":"J Ren Care"},{"key":"10.1053\/j.jrn.2013.11.004_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.ajkd.2011.12.025","article-title":"Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status","volume":"60","author":"Lopes","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2013.11.004_bib11","first-page":"525","article-title":"Challenge of phosphorus control in hemodialysis patients: a problem of adherence?","volume":"23","author":"Arenas","year":"2010","journal-title":"J Nephrol"},{"key":"10.1053\/j.jrn.2013.11.004_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2369-9-2","article-title":"A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease","volume":"9","author":"Karamanidou","year":"2008","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.jrn.2013.11.004_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/2047-783X-14-5-185","article-title":"Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature","volume":"14","author":"Schmid","year":"2009","journal-title":"Eur J Med Res"},{"key":"10.1053\/j.jrn.2013.11.004_bib14","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/ndt\/gfq602","article-title":"Improving CKD-MBD management in haemodialysis patients:barrier analysis for implementing better practice","volume":"26","author":"Toussaint","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jrn.2013.11.004_bib15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.ajkd.2010.03.002","article-title":"Barriers to adult hemodialysis patients' self-management of oral medications","volume":"56","author":"Browne","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2013.11.004_bib16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2013.11.004_bib17","doi-asserted-by":"crossref","unstructured":"Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome B. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis . Nephrol Dial Transplant. 2013. Epub 2013\/09\/07. doi: 10.1093\/ndt\/gft280. PubMed PMID: 24009281.","DOI":"10.1093\/ndt\/gft280"},{"key":"10.1053\/j.jrn.2013.11.004_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1185\/030079905X41453","article-title":"A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis","volume":"21","author":"Finn","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.jrn.2013.11.004_bib19","doi-asserted-by":"crossref","first-page":"c15","DOI":"10.1159\/000149239","article-title":"Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment","volume":"110","author":"Hutchison","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"10.1053\/j.jrn.2013.11.004_bib20","doi-asserted-by":"crossref","first-page":"c8","DOI":"10.1159\/000084653","article-title":"Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate","volume":"100","author":"Hutchison","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1053\/j.jrn.2013.11.004_bib21","doi-asserted-by":"crossref","first-page":"c61","DOI":"10.1159\/000088932","article-title":"Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study","volume":"102","author":"Hutchison","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"10.1053\/j.jrn.2013.11.004_bib22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5414\/CNP72252","article-title":"Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study","volume":"72","author":"Sprague","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.jrn.2013.11.004_bib23","first-page":"683","article-title":"A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice","volume":"23","author":"Arenas","year":"2010","journal-title":"J Nephrol"},{"key":"10.1053\/j.jrn.2013.11.004_bib24","unstructured":"Sanofi-Aventis US LLC. Renvela\u00ae (sevelamer carbonate): US prescribing information. http:\/\/www.renvela.com\/\u223c\/media\/RenvelaUS\/Files\/RV382_Renvela_PI_08.2011.pdf. Accessed October 10,\u00a02013."},{"key":"10.1053\/j.jrn.2013.11.004_bib25","unstructured":"Shire US Inc. Fosrenol\u00ae (lanthanum carbonate): US prescribing information. http:\/\/pi.shirecontent.com\/PI\/PDFs\/Fosrenol_USA_ENG.pdf. Accessed October 10,\u00a02013."},{"key":"10.1053\/j.jrn.2013.11.004_bib26","unstructured":"Sanofi-Aventis US LLC. Renagel\u00ae (sevelamer hydrochloride): US prescribing information. http:\/\/www.renassist.com\/media\/pdf\/GEN-Renagel%20PI%202011%20NEW.pdf. Accessed October 10,\u00a02013."},{"key":"10.1053\/j.jrn.2013.11.004_bib27","unstructured":"Shire Pharmaceuticals Limited. Fosrenol\u00ae (lanthanum carbonate) oral powder: summary of product characteristics. http:\/\/www.medicines.org.uk\/EMC\/medicine\/26625\/SPC\/Fosrenol+750mg+&+1000mg+oral+powder\/.Accessed October 10,\u00a02013."}],"container-title":["Journal of Renal Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051227613002136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051227613002136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T23:30:33Z","timestamp":1538868633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051227613002136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1051227613002136"],"URL":"https:\/\/doi.org\/10.1053\/j.jrn.2013.11.004","relation":{},"ISSN":["1051-2276"],"issn-type":[{"value":"1051-2276","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}